Atria Wealth Solutions, Inc. Seagen Inc. Transaction History

Atria Wealth Solutions, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$191.51 - $216.16 $22,023 - $24,858	-115 Reduced 10.77%	953 $202,000
Q2 2023 Aug 03, 2023	SELL	$187.64 - $206.25 $101,325 - $111,375	-540 Reduced 33.58%	1,068 $205,000
Q1 2023 Aug 22, 2023	BUY	$127.59 - $203.08 $52,822 - $84,075	414 Added 38.76%	1,482 $300,000
Q1 2023 Jun 14, 2023	BUY	$127.59 - $203.08 $16,076 - $25,588	126 Added 8.5%	1,608 $325,000
Q1 2023 May 10, 2023	SELL	$127.59 - $203.08 $16,076 - $25,588	-126 Reduced 7.84%	1,482 $300,000

Q4 2022 Aug 30, 2023	BUY	$117.37 - $139.17 $63,379 - $75,151	540 Added 50.56%	1,608 $206,000
Q4 2022 Feb 13, 2023	SELL	$117.37 - $139.17 $16,314 - $19,344	-139 Reduced 7.96%	1,608 $206,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $809,590 - $1.08 Million	-5,985 Reduced 77.41%	1,747 $239,000
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $218,599 - $360,273	2,009 Added 35.1%	7,732 $1.37 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $684,528 - $903,375	5,723 New	5,723 $824,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Atria Wealth Solutions, Inc., based on Form 13F filings with the SEC.

Stay updated on Atria Wealth Solutions, Inc. with notifications on news.